Skip to content
Wired News Engine – Lifestyle
Author:
Ambros Therapeutics, Inc.
Ambros Therapeutics Announces First Patient Dosed in Pivotal CRPS-RISE Phase 3 Clinical Trial of Neridronate in Patients with Complex Regional Pain Syndrome Type 1
June 8, 2026
Ambros Therapeutics Announces Notice of Allowance for New U.S. Patent Application Covering Neridronate for Complex Regional Pain Syndrome Type 1
March 31, 2026